reducing the amount of bleeding after laminectomy and posterior thoracolumbosacral fusion.
Conditions
Interventions
Intervention group: fibrinogen Manufacturer: CSL BEHRING [Germany].
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients with a surgical treatment plan of laminectomy and posterolateral spinal fusion. Patients who underwent laminectomy of greater than or equal to 2 spaces with posterior fusion with pedicle screws (CD insertion) Patients aged at least 18 and up to 65 years old Patients referred to Dr. Shariati Hospital affiliated with Tehran University of Medical Sciences between 1404 and 1405
Exclusion criteria
Exclusion criteria: Pregnancy, breastfeeding, and OCP use Use of beta-blockers, calcium blockers, digoxin, tricyclic antidepressants, anticoagulants, clonidine, alcohol and drug abuse Abnormalities in tests/PTT/INR/PT Hematological and coagulation diseases, respiratory, cardiovascular, cerebrovascular, hepatic and renal failure History of any thrombotic events such as CVA/MI Patients who received Packed Cell prior to surgery CPR history Tumor in the surgical site
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bleeding volume in cc. Timepoint: 6 hours, 24 hours, and 48 hours post surgery. Method of measurement: Hemovac drain. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarzan Jafarnejad
Tehran University of Medical Sciences
Outcome results
None listed